All Posts By

Luciana Nofal

THANK YOU ODAC SPONSORS

By | ODAC

NEW YORK, (January 13, 2021) – Luciana Halliday Nofal, VP Marketing and Client Relations SanovaWorks

ODAC Dermatology Aesthetic and Surgical conference 

This year, due to the global pandemic, SanovaWorks is hosting ODAC Dermatology, Aesthetic and Surgical conference, virtually. ODAC is committed to providing high-quality education in an engaging virtual format with top speakers and important topics.

With nearly 1,000 US attendees registered, ODAC will provide a unique virtual experience that will continue to drive dermatology education and networking forward.

We appreciate all the effort that it takes to change direction and to make such an important and impactful event happen. We are deeply grateful to our sponsors, faculty and attendees.

Please take a moment to acknowledge and thank our gracious supporters by visiting their sponsor page in ODAC Virtual app.

Platinum and Featured Sponsors  

Amgen logo

Please see the resources below to discover our data and explore our resources in our sponsor page.

 

Cassiopea, Inc. is a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action to address long-standing and essential dermatological conditions such as acne, androgenetic alopecia and genital warts. Learn more about our company at www.cassiopea.com.

Our commitment to dermatology is built around a senior leadership team with deep roots and experience in the specialty. The management team is focused on providing unique treatment options, and to drive continued research and development in Dermatology, moving us to the forefront of the U.S. market.

We are excited to support dermatology healthcare professionals by contributing to the ODAC 2021 Conference.

Galderma, the world’s largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio of prescription medicines, aesthetics solutions and consumer care products. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com/us.

 

Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.

Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders. The Company is advancing a diversified portfolio of clinical candidates across Oncology and Inflammation & Autoimmunity. Our research and development efforts in Dermatology are focused on a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo, and hidradenitis suppurativa.

Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For more information, visit Incyte.com and follow @Incyte.

Visit the Incyte Dermatology Virtual Booth.

 

Neutrogena Logo

At Aveeno®, groundbreaking science transforms nature’s ingredients into clinically proven products that help soothe, strengthen, and restore the moisture barrier. Our oat, soy, and feverfew ingredients—derived from nature and uniquely formulated to optimize skin health and beauty—are supported by 75 years of published data, demonstrating the scientific rigor behind every result. Visit AveenoMD.com to learn about our new products, plus access clinical resources, patient resources, and product samples.

The #1 dermatologist recommended skincare brand continually elevates the science of skincare, delivering new products and innovations that support your treatment guidance. Visit NeutrogenaMD.com to learn what’s new, plus access clinical resources, patient resources, and product samples. NeutrogenaMD.com – dedicated to dermatology professionals.

 

La Roche-Posay logo

Our brands are dedicated to dermatology with offerings in professional skincare and cosmetics. Each brand is created by dermatologists or works in partnership with dermatologists to meet the health and safety standards for patients. Please visit the L’Oréal booth.

 

Novartis logo

Novartis is a leading global medicines company, using innovative science and digital technologies to create treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. Find out more at www.novartis.com.

We hope you will take a moment to visit the COSENTYX® (secukinumab) Virtual Booth Experience to learn more about the Complete Cosentyx Approach.

 

Ortho Dermatologics is a specialty pharmaceutical business with the number one prescribed acne franchise and a portfolio of dermatology treatments in additional therapeutic areas including atopic dermatitis, fungal infections and psoriasis. Led by a team with deep experience in dermatology, we are dedicated to building meaningful connections with healthcare providers and their patients. Our ongoing commitment to the dermatology community shows through our pipeline of novel compounds and focused philanthropic activity here and around the globe.

 

Regeneron is a leading biotechnology company that invents medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation around the globe.

Please click the link below to visit our virtual booth!
https://www.dupixenthcp.com/virtualcongress

 

At UCB, we come together every day to work, laser-focused, on a simple question: How will this create value for people living with severe diseases? Patient value is not just what we say, but how we how we live. It is our culture of care, embodied by our patient value strategy. That’s because how we do business – from discovery to development to delivery – has been transformed and redesigned around the patient and their individual experience. Patients are at the heart of everything we do, inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. By fulfilling our commitment, driving innovation, and providing patients a meaningful experience, more impactful solutions are on the horizon.

With a team of approximately 7,500 employees and operations in nearly 40 countries, we are a global biopharmaceutical company investing more than a quarter of our revenue in cutting-edge scientific research to meet unmet patient needs. Global headquarters are in Brussels, Belgium, with U.S. headquarters in Atlanta, Georgia. Additional U.S. UCB sites include global clinical development in Raleigh, North Carolina, research supporting UCB’s pipeline in Boston, Massachusetts (Bedford and Cambridge), Seattle, Washington, and Durham, North Carolina as part of our acquisition of Element Genomics, as well as an office in Washington, D.C.

CLICK to ENTER Virtual Experience

 

Official Media Partners

THANK YOU, SKIN OF COLOR UPDATE VIRTUAL 2020 SPONSORS

By | Skin of Color Update

NEW YORK, (August 25, 2020) – Luciana Halliday Nofal, VP Marketing and Client Relations SanovaWorks

Skin of Color Update Virtual 2020

This year, due to the global pandemic, for the first time, we are hosting Skin of Color Update 2020, virtually. Even though we will miss seeing everyone in person, we are committed to the health and safety of our employees, clients, and other support staff required to run a live event. We appreciate all the effort that it takes to change direction and to make such an important and impactful event happen. We are deeply grateful.

SanovaWorks would like to recognize Skin of Color Update Virtual 2020 supporters

Aveeno®

At Aveeno®, everything is rooted in our belief that balance is the key to wellbeing. That’s why we use groundbreaking science to transform nature’s ingredients into products that rebalance and renew your skin.

Allergan Aesthetics 

At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Learn more: www.AllerganAesthetics.com.

GALDERMA

Given the important role our skin plays in each of our daily lives, Galderma’s focus on science-based solutions for skin health is the way we seek to enhance the quality of people’s lives.

Journal of Drugs in Dermatology

The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology.

L’Oréal Group Dermatological Brands – CeraVE, La Roche-Posay, Skinceuticals, Dermablend

At L’Oréal, we share a common purpose to:  Create the beauty that moves the world.

CeraVe

In 2005, CeraVe’s dermatologists developed a line of skincare products enriched with a blend of three essential ceramides (ceramides 1, 3, and 6-II), fatty acids, and other lipids to help repair and strengthen the skin’s natural barrier.

LA ROCHE- POSAY

Recommended by 90,000 dermatologists worldwide, La Roche-Posay skincare is formulated with high efficacy and safety standards in a full range of products to address skin needs, even sensitive skin.

SKINCEUTICALS

Made in the USA, our clinical skincare is used by dermatologists, plastic surgeons, and medi-spas for daily homecare and to complement aesthetic procedures.

Dermablend

The choice to wear makeup is a powerful one – Dermablend Professional wants to strip away the judgement associated with this choice.

LEO Pharma

Leo Pharma has a 100+ year history as a specialty pharmaceutical company, committed to the discovery and development of novel drugs for patients.

Lumenis

Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF).

Neutrogena®

Neutrogena® the #1 Dermatologist Recommended skincare brand offers a wide range of skin and hair care products.

Regeneron/Sanofi

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. As the specialty care global business unit of Sanofi, our work is focused in the areas of rare diseases, rare blood disorders, multiple sclerosis, oncology, and immunology.

PCA Skin

PCA SKIN is the innovator of the modified and enhanced Jessner’s peel and over the past decades our line of blended chemical peels has expanded to include treatment options for all skin types, ethnicities and conditions.

Sciton

Sciton was created to provide advanced lasers and light sources to the aesthetic medical markets. With over a decade of performance behind us, Sciton systems have become the standard of care in each application our products address.

Senté

Founded by biotech entrepreneurs and scientists, SENTÉ® is driven by a sense of wonder and scientific discovery. Our mission is to challenge beliefs and the status quo within the skincare industry.

Pfizer

Our purpose is grounded in our commitment to fund programs that provide public benefit, advance medical care and improve patient outcomes. Our belief is that all people deserve to live healthy lives. This drives our desire to provide access to medicines that are safe, effective, and affordable.

ODAC

ODAC Dermatology, Aesthetic and Surgical Conference (ODAC) is a distinguished ACCME accredited dermatology conference designed to meet the needs of medical and aesthetic dermatology providers in the 21st century.

 

This live virtual and enduring continuing education activity is supported through independent medical education grants provided by:

Allergan

Galderma Laboratories, L.P

Novartis Pharmaceuticals Corporation

Sanofi Genzyme and Regeneron Pharmaceuticals

UCB, Inc.

Sponsorships available Skin of Color Update 2020 Virtual

Through grant support, sponsorship & exhibitor opportunities:

  • Gain direct access to 300+ dermatology experts and influential faculty on our virtual platform
  • Increase your brand equity with this elite group of dermatology physicians through webinar product forums
  • Showcase your medical products, aesthetic treatments and device technology on our virtual event platform, through virtual product forums and more
  • Generate leads and expand your network with this niche group in the sponsor and exhibitor marketplace gallery
  • Expand your reach with an outflow publication in the Journal of Drugs in Dermatology (JDD)

Email [email protected] to become a Skin of Color Update Virtual Supporter.

Space is limited and sponsorship is not guaranteed. 

Luciana Halliday Nofal
VP of Marketing and Client Relations 

COVID 19: URGENT MEDICAL AND AESTHETIC ISSUES FOR DERMATOLOGY

By | Press

NEW YORK, (April 10, 2020) – Luciana Halliday Nofal, VP Marketing and Client Relations SanovaWorks

Polling Questions Answered by Dermatologists and Dermatology Healthcare Practitioners

Moderated by Joel L. Cohen, a panel of dermatologist and dermatology industry experts including Adam Friedman, MD, Neal Bhatia, MD, Bill Humphries (Ortho Dermatologist), Sue Ellen Cox, MD, Kavita Mariwalla, MD and Carrie Strom (Allergan) joined the COVID-19 conversation discussing the questions that are on the minds of many dermatologists and healthcare practitioners in the country. The initial broadcast attracted 1,900 registrants and nearly 800 attendees participated. More than 85% of the audience were of dermatology physicians, with the remaining participants made up of dermatology residents, fellows, nurse practitioners and physician assistants.  Attendees were polled a variety of questions regarding how their practice was responding to COVID-19.

Adoption of Teledermatology

Regarding how physicians were adapting to the use of teledermatology, almost one third (30.71%) of those who answered saw no teledermatology patients in the preceding week, almost forty percent (39.98%) saw less than five per day, under ten percent (9.06%) saw more than 11 patients a day, with the remainder of respondents (21.26%) saw between five and ten patients per day in the previous week.

When asked the average time a teledermatology encounter takes (physician log on to physician log off), almost one third (31.25% said five to ten minutes, almost half (47.12%) took from eleven to twenty minutes, less than four percent (3.85%) took more than thirty minutes for the encounter, while the remaining (17.79%) took twenty-one to thirty minutes.

Urgent Dermatologic Cases

When the subject of what urgent dermatologic cases besides melanoma the participating dermatologists were seeing live in their practice, almost one third (29.41%) answered “zoster, versus concerning rash”, more than forty percent (41.18%) answered “spot checks of atypical pigmented lesions”, just over a quarter (26.47%) were seeing “invasive growing squamous cell” and under three percent (2.94%) were seeing live patients in their office for tumors around the orbit.

Patient Access to Medications

Almost one half of those who responded (47.85%) answered that they were having difficulty getting anti-malarials (HCQ, Chloroquine) for their patients that are on them, while the other half (52.15%) were not.

Return to Business for Cosmetic Practices 

Almost forty percent of those polled (38.69%) were optimistic that their practice would be back to “normal” (seeing cosmetic patients full time) in July, with an almost even spread of the remainder of respondents believing their practice would be back to normal in June (16.58%), August (15.58%), September (14.57%) or October and beyond (14.57%).

Planning for the year ahead

When asked how likely participants were to register now for a conference taking place in the fall, winter or spring, the majority of those who answered, said they were likely to register now for meetings during any of those time frames, ranging from almost half of respondents (47.75%) who would be likely to register now for a fall meeting, almost two-thirds (62.64%) for a meeting in the winter, and more than three-quarters (77.78%) would register now for a meeting taking place in the Spring. 

We look forward to asking more questions in the future to help the community provide the support it needs right now.

The on-demand broadcast has attracted over 500 registrants as of April 9th and is available on JDDonline.com.

Click here for access to Part I

Part II:  COVID-19: Your Questions Answered

COVID-19: Your Questions Answered, part II of the webinar series, was broadcasted on April 7, 2020. 

During this webinar dermatology experts and other thought leaders examined the legal and financial concerns of dermatology providers during the global coronavirus pandemic. David Goldberg, MD, JD lead a panel of experts, Joel L Cohen, MD, Jeffrey Dover, MD, Gunga Mukkavilli, CPA, and Janel Ablon, Esq. through discussions on furlough vs. layoffs; mortgage and rent relief programs; the CARES Act; and other important and current legal and financial matters for dermatologists. 

A second panel of experts including Joel L Cohen, MD and Jeffrey Dover, MD, from the previous panel, joined by Elizabeth Tanzi, MD, and moderated by Adam Friedman, MD, answered questions, discussed practical tips you can use in your practice right now; and how to move forward with patient care. Part II attracted 1,300 registrants with nearly 700 attendees.

Staffing, financials, and teledermatology

Over half of those polled (53.42%) responded that since the pandemic they have had to furlough staff and almost one quarter (23.6%) hadn’t but believed they may have to in the future. 

More than three-quarters of respondents (75.46%) said that their receivables in March compared to February are decreased greatly, while less than eight percent said their receivables were “about the same” (5.52%) or had “increased slightly” (2.45%). The remainder of respondents (16.56%) indicated that their receivables had decreased slightly.

With regards to financial assistance programs, almost all respondents (89.15%) said that they applied for the Paycheck Protection Program a Small Business Association loan that helps businesses keep their workforce employed during the COVID-19 crisis. In addition to this, almost one third (28.68%) had applied for the EIDL (Economic Injury Disaster Loan Emergency Advance), just under eight percent (7.75%) had applied for other Federal loans or grants, six percent (6.2%) applied for state loans or grants, and just two percent (2.33%) had found and applied for other loans or grants. 

Most respondents (78.42%) were not planning on borrowing from their retirement savings, while a further almost twenty percent (18.42%) were unsure and just three percent (3.16%) indicated they were planning on borrowing from their retirement fund,

Only a very small number of those polled (8.84%) feel experienced with teledermatology and use it as a normal part of their practice, and less than five percent (4.42%) were not planning on using it at all. Almost all respondents (86.74%) had little to no experience in teledermatology. Almost sixty percent (58.01%) had started teledermatoligy since the pandemic began, a further twenty percent (21.55%) had started before the pandemic but considered themselves a beginner, and a further seven percent (7.18%) had not started but wanted to.

We hope you enjoy watching and listening to these panels of experts discuss the latest issues in dermatology and we look forward to bring you more episodes.

The on-demand broadcast of Part II will be available on April 11, 2020 on JDDonline.com.

Click here for Part II

SANOVAWORKS COVID-19 RESOURCES

 

SANOVAWORKS COVID-19 RESOURCES

By | Press

NEW YORK, (Apr. 9th, 2020) – Luciana Halliday Nofal, VP Marketing and Client Relations

In response to the needs of the SanovaWorks community, our brands have developed COVID-19 resources.

COVID 19 part I dermatology JDD Next Steps SanovaWorks

On April, 1, 2020, the Journal of Drugs in Dermatology (JDD) and SanovaWorks brands launched Part I of the webinar series: COVID-19: Urgent Dermatology and Aesthetic Issues for Dermatology.

Over the course of the 2 hours, Joel L. Cohen, MD and 6 different thought leaders joined the COVID-19 conversation, discussing the pressing questions that are on the minds of many dermatologists and providers in the country. The initial broadcast attracted 1,900 registrants and nearly 800 attendees comprised of physicians, residents, fellows, nurse practitioners and physician assistants.  Attendees were interested and engaged throughout the entire 2 hours with a 76% average attentiveness and 72% average interest rating.

The on-demand broadcast has attracted over 500 registrants as of April 9th and is available on JDDonline.com.

Part II COVID in Dermatology Webinar Financial and Legal

On April 7, 2020, Part II of the webinar series was broadcasted: COVID-19: Your Questions Answered. Dermatology experts and thought leaders examined the legal and financial concerns of dermatology providers during the global coronavirus pandemic. Experts discussed furlough vs. layoffs; mortgage and rent relief programs; the CARES Act; the pros and cons of leveraging NPs or PAs for teledermatology and more. Then, hear questions answered by our panel of experts; discussed practical tips you can use in your practice right now; and how to move forward with patient care. Part II attracted 1,300 registrants with nearly 700 attendees. Attendees were engaged and interested throughout with an 82% attentiveness average and 75+% interest rating.

The on-demand broadcast of Part II will be available on April 11, 2020 on JDDonline.com.

Next Steps in Dermatology, a resource for young dermatologists and residents, recently launched a COVID-19 News and Resource Center. Next Steps in Derm COVID-19 News & Resources Center offers a curated selection of relevant news and resources from truthworthy sources to help physicians navigate the COVID-19 pandemic.

Resources include:

  • COVID-19 Webinars
  • Free CME
  • COVID-19 Related Podcast Episodes
  • COVID-19 PubMed Articles in JAAD, JDD, etc.
  • Recommendations from AAD, AMA, etc.
  • Guidance from HIPAA, Medicare, and on Telehealth
Friedman Dermatologist ODAC disaster preparedness

ODAC AND JDD HELP IDENTIFY NEED FOR DISASTER TRAINING AMONG DERMATOLOGISTS

By | ODAC, Press

A new study from the George Washington University found that many dermatologists are unprepared to respond to biological disasters and that the specialty would benefit from formal preparedness training.

WASHINGTON (Jan. 30, 2020) — The dermatology community is inadequately prepared for a biological disaster and would benefit from a formal preparedness training program, according to a study from the George Washington University (GW). The article is published in the Journal of Drugs in Dermatology.

Natural and man-made disasters can cause a range of dermatologic conditions due to environmental exposures, such as secondary infections following a flood, irritation from blistering agents used in chemical warfare, and acute and chronic effects of cutaneous radiation syndrome. A 2003 survey revealed that 88% of dermatologists felt unprepared to respond to a biological attack — this new survey shows that the need for training still exists.

“Recognizing and diagnosing the conditions that can arise following a disaster requires diagnostic acumen, knowledge on reporting, and short- and long-term management strategies,” said Adam Friedman, MD, interim chair of the Department of Dermatology at the GW School of Medicine and Health Sciences and senior author on the study.

This current survey from an interdisciplinary team of dermatology and emergency medicine researchers, led by Emily Murphy, a research fellow in the GW Department of Dermatology, examines whether the field of dermatology has advanced in its bioterrorism preparedness.

The survey, disseminated via the ODAC Dermatology, Aesthetic & Surgical conference listserv, found that only 28.9% of respondents received training in disaster preparedness and response. The respondents to the survey frequently commented that they felt dermatologists should be prepared for bioterrorism-related cutaneous diseases, such as anthrax or smallpox-related diseases, as well as infections resulting from natural disasters.

Similar to the 2003 survey, the authors found that few dermatologists received adequate bioterrorism preparedness training. Even among those who had reported training, many indicated they felt ill prepared to manage patients affected by disasters, especially biological attacks and nuclear or radiological events.

“While few respondents to the survey were trained in disaster preparedness, it is encouraging that 75% reported that it should be included in dermatology training,” Friedman said. “It is a necessary tool to advance the field.”

James Phillips, MD, section chief of disaster and operational medicine in the GW Department of Emergency Medicine, director of the GW Disaster Medicine Fellowship, and co-author on the study, agreed: “My fellows and I found great value in partnering with our dermatology colleagues for this project. It is my firm belief that, while disaster medicine and emergency management primarily fall within the scope of emergency medicine and trauma surgery, education, and training for other specialties is of great value and is virtually unexplored. In an increasingly complex disaster environment, we welcome such research collaborations with other GW specialists.”

###

The article, titled “A Survey of Dermatologists’ Preparedness for Natural and Man-made Disasters,” is published in the Journal of Drugs in Dermatology and can be found at jddonline.com/articles/dermatology/S1545961620P0016X/1.

Susan Weinkle ODAC Award

ODAC VICE CHAIR SUSAN WEINKLE, MD RECOGNIZED AS OUTSTANDING EDUCATOR & MENTOR

By | ODAC, Press

ORLANDO, Fla. (Jan. 21, 2020) – The ODAC Dermatology, Aesthetic & Surgical Conference, in partnership with the Journal of Drugs in Dermatology (JDD), honored dermatologist Susan H. Weinkle, MD, with the Outstanding Educator & Mentor in Dermatology Award at the conference held January 17-20 in Orlando, Fla.

The award recognizes individuals who have demonstrated a long-standing commitment to educating and mentoring the next generation of dermatologists, and who have devoted a major portion of his or her professional life to enhancing the practice and profession of dermatology through education.

“It is a pleasure and an honor to recognize the tireless work of exceptional leaders in dermatology,” said Shelley Tanner, CEO and president of SanovaWorks, which produces the JDD, ODAC, Derm In-Review and Next Steps in Dermatology. “Not only do these dermatology leaders dedicate their entire lives to benefiting patients every day, but after the “work day” ends, they spend countless hours involved in activities to improve the specialty’s future. We congratulate Dr. Weinkle for being chosen for this award.”

“Physicians around the globe have learned so much from Dr. Susan Weinkle,” said dermatologist and ODAC vice conference chair Joel Cohen, MD. “Susan has given all of us in aesthetics so much of her time and energy, and I am honored to present this award to her.”

Dr. Weinkle is an assistant clinical professor of dermatology at the University of South Florida, Tampa, Fla. She is a past president of the Women’s Dermatological Society and the American Society for Dermatologic Surgery. In addition, Dr. Weinkle is a former committee chair and member of the board of directors of several dermatology organizations, including the American Academy of Dermatology, Dermatology Foundation, and Florida Society of Dermatology and Dermatologic Surgery. Dr. Weinkle is in private practice in Bradenton, Fla., specializing in Mohs Micrographic Surgery and cosmetic dermatology. Her daughter, Allison, will join the practice upon completion of her dermatology residency and fellowships in cosmetic dermatology and Mohs Micrographic Surgery.

The recipient of the Outstanding Educator & Mentor in Dermatology Award, given by the Journal of Drugs in Dermatology, is nominated and chosen through the recommendation of a panel of senior national thought-leaders in dermatology, a committee of dermatology practitioners and several industry leaders.

 

Skin of Color update on-demand online videos

SKIN OF COLOR UPDATE ON-DEMAND

By | Skin of Color Update

NEW YORK (Dec. 4, 2019) – Skin of Color Update, a product of SanovaWorks, has launched an on-demand video package that expands the program’s reach. The highest attendee-rated sessions from Skin of Color Update 2019 are now available as online videos as part of the “Best of Skin of Color Update” package. Skin of Color Update is the largest continuing education event dedicated to trending evidence-based research and new practical pearls for treating skin types III – VI.

“We are humbled and honored that our Skin of Color Update conference has been consistently sold out,” said Skin of Color Update co-chair and founding dermatologist Eliot Battle, MD. “It’s vital for every dermatologist to know how to safely and effectively treat skin of color. As such, Skin of Color Update is moving to a larger venue next year, and dermatologists who are unable to attend in person can now access lecture material on their computers.”

On-demand lectures include:
• “Pearls for the Diagnosis and Treatment of Atopic Dermatitis and Eczema” with Andrew Alexis, MD, MPH
• “Complex Medical Cases” with Andrew Alexis, MD, MPH, and Ted Rosen, MD
• “Surgical Approaches for Keloids” with Maritza Perez, MD
• “Hair & Scalp Disorders Treatment Strategies: What, How and When?” with Heather Woolery-Lloyd, MD
• “Pearls and Strategies for Preventing Laser Complications” with Eliot F. Battle, Jr., MD.

Each video is in-sync with slides and audio. The content focuses on expert techniques, real-life clinical cases and expert pearls immediately useful in practice.

Skin of Color Update Dermatology On-Demand

 

 

 

 

The “Best of Skin of Color Update” package is available by clicking the On-Demand tab at SkinofColorUpdate.com.
Skin of Color Update is a product of SanovaWorks, publisher of the Journal of Drugs in Dermatology (JDD) and producer of the ODAC Dermatology, Aesthetic & Surgical Conference.

Sanovaworks JDD oral Collagen New York Times

SANOVAWORKS JDD ARTICLE CITED IN NEW YORK TIMES

By | Press

NEW YORK (Nov. 19, 2019) – Oral Collagen Supplements: Are they Fountain of Youth or Snake-oil? The New York Times cites SanovaWorks publication, the Journal of Drugs in Dermatology (JDD).

In January 2019, the JDD (Journal of Drugs in Dermatology) published “Oral Collagen Supplementation: A Systematic Review of Dermatological Applications” published a literature review and analysis of eleven scientific studies that all met defined criteria. All studies included in the review were considered “randomized-controlled studies” lending weight to their voice. The study concluded that results were optimistic for both short and long-term use of oral collagen supplements for wound healing and skin aging. Additionally, skin elasticity, hydration and collagen density were seen to increase with use. The authors of the study cited that collagen supplementation was generally safe with no reported adverse events however advised that further studies were required to provide better clinical guidelines for the use of collagen. SanovaWorks blog for young dermatologists and residents, Next Steps in Derm, provides a summary of the JDD article here.

Collagen is a protein that makes up approximately 80% of our skin and yet declines in volume at a rate of about 1% annually from our 20’s, says Dr. Whitney Bowe, a board-certified dermatologist. The question is, can you replenish your skin and youthful look through applying additional collagen on your skin or consuming similar supplements? The New York Times took a closer look at this subject citing JDD article.

You can find the New York Times article here: https://www.nytimes.com/2019/11/09/style/self-care/collagen-benefits.html

Dr. Bowe believes that the studies, “though small and preliminary,” show promise. Dr. Bowe has begun recommending oral collagen to her patients and has observed noticeable positive changes in skin elasticity, firmness and hydration.

“With volume of information available to the consumer it is imperative that independent scientific studies continue to be conducted and reported on to protect the consumer and patient. This is what we strive to do with the JDD” says Shelley Tanner, President of SanovaWorks, publisher of JDD (Journal of Drugs in Dermatology).

Sanova Works SanovaWorks launches Derm In-Review

SANOVAWORKS LAUNCHES NEW DERM IN-REVIEW STUDY TOOLS

By | Derm In-Review, Residents

NEW YORK, NY (Nov. 1, 2019) – SanovaWorks launches new Derm In-Review Study Guide and Online Image Companion free for dermatology residents and dermatology professionals.

Emerging and established academic leaders from all of the various fields within dermatology have come together to redesign and update the most comprehensive study guide and online image companion in dermatology board review. Derm In-Review’s 2019/2020 study guide and online image companion match the new and pending changes to examinations that lay ahead for dermatology residents. Changes include clinical guidelines, high-def, high-quality digital images and delineation of information appropriate for the Basic, Core and Applied exams as outlined in the Exam of the Future.

Study Guide Updates

The Derm In-Review study guide is over 400 pages and formatted for quick study and easy reference. It includes call-out text, tip boxes, highlighted text, mnemonic boxes and 300+ full-color images.  The study guide is comprised of five chapters:

Chapter 1: Basic Science (including Immunodermatology)

Chapter 2: Medical Dermatology

Chapter 3: Pediatric Dermatology

Chapter 4: Surgical Dermatology

Chapter 5: Dermatopathology

Request or Download the Study Guide

2019/2020 Derm In-Review study guides will be provided to all US dermatology residents in print. A free electronic version of the study will also be available for download on the Derm In-Review website. Log in or create a complimentary account and then go to Study Guide Request in your dashboard. Special thanks goes to the Derm In-Review advertisers and corporate sponsors: Aurora Diagnostics, Celgene, Lilly, and Novartis.

In addition, all of the study guide clinical images as well as additional clinical images will be available in the Online Image Companion.  This companion includes nearly 400 original images and will allow users to log on to the website to enlarge the images for enhanced viewing.  Over 100 images are dedicated to dermatopathology board review.

Exam of the Future

The American Board of Dermatology (ABD) is restructuring the In-Training and Certification exams—moving from our current approach of emphasizing knowledge retention and visual diagnosis to exams that better emphasize the application of knowledge using clinically relevant case scenarios. The Exam of the Future will be a staged evaluation with a BASIC exam designed for first-year residents, covering dermatology fundaments; CORE exam modules testing more advanced knowledge of senior residents about dermatology’s major clinical areas; and an APPLIED exam given after residency, which tests the ability to apply knowledge in clinical situations.

Visit the Derm In-Review website for more information.  If you would like to advertise or support Derm In-Review, please reach out to Luciana Nofal at [email protected].  Derm In-Review is a produced and published by SanovaWorks.

 

 

MOC CertLink ODAC Dermatology

DR. STRATMAN TO PRESENT MOC CERTLINK AT ODAC

By | ODAC

NEW YORK (Oct. 30, 2019) – Erik J. Stratman, MD, 2019 President of the American Board of Dermatology (ABD), to present on Maintenance of Certification (MOC) CertLink in January at ODAC Dermatology, Aesthetic and Surgical conference.

Changes to MOC

A major shift in continuing certification is coming for board-certified dermatologists in January. Erik J. Stratman, MD will present, “Changes to Your MOC Requirements: What Every Dermatologist Should Know about CertLink,” on January 17th, 2020 at the J.W. Marriot in Orlando, Florida.

Workshop Description

Dr. Stratman will walk-through the CertLink® MOC program and demonstrate its design, rationale and navigation. According to the ABD, CertLink provides the utmost flexibility in MOC and provides an alternative to the one-time, sit-down, high stakes in-person MOC examination. Dermatologists will be able to go online and take test questions in the convenience of their own home or office at various times throughout the year.

ABD MOC CertLink®

CertLink® is a longitudinal testing platform. The platform is designed to test and build medical knowledge in a “test to competence” type model.  In addition, CertLink® will keep dermatologists up to date by providing the latest articles from dermatology subspecialties. CertLink™ assessment platform is powered by American Board of Medical Specialties (ABMS).

Registration and Fees

The pre-conference workshop is provided complimentary for dermatologists registered for ODAC 2020.

About ODAC

Attend ODAC to stay connected, informed, and up-to-date in dermatology. ODAC (previously Orlando Derm) is one of the largest and most prestigious conferences of the year. ODAC attracts a national audience of over 650 US Dermatology Physicians, Dermatology Residents, Nurse Practitioners and Physician Assistants.

Visit orlandoderm.org to register for ODAC and attend this workshop.  ODAC is a product of SanovaWorks.

 

 

ODAC Dermatology Sold Out Hot Topics

ODAC OFFERS MORE ACCESS TO HOT TOPICS

By | ODAC, Press

New York (Oct. 28, 2019) – The ODAC Dermatology, Aesthetic & Surgical Conference (ODAC) is extending its program for 2020 with additional time for ODAC hot topics, general sessions and workshops.

Attendee Feedback

“We’ve listened to our attendees and altered our program to provide greater access to the hottest topics in the field,” said Perry Robins, MD, dermatologist and founder of ODAC. “Our sessions are led by expert faculty who provide the latest research and clinical updates on a variety of medical, surgical and aesthetic dermatology topics.”

The 2020 conference will be held January 17-20 at the JW Marriott in Orlando, Florida. ODAC, which started in 2003, attracts more than 650 dermatology physicians, residents, nurse practitioners and physician assistants each year.

The 2020 conference focuses on clinical dermatology updates, new treatments, new uses for old treatments, new product lines, changes to therapeutic guidelines, and hot and controversial topics. The interactive learning experience includes more than 20 workshops and more than 5 hours of live aesthetic demonstrations. In addition, ODAC offers hands-on sessions, live Q&As and opportunities to dialogue with leaders in the field. Up to 31 AMA PRA Category 1 Credits™ are available.

One-of-a-Kind

“There is no other conference like ODAC,” said dermatologist and conference chair James Spencer, MD, MS. “Each presentation provides practical pearls you can implement in your practice. This will be my 17th ODAC, and this meeting keeps getting better and better.”

In addition, three pre-conference workshops are available the first day of the conference:

  • “Comprehensive Nonsurgical Aesthetic Rejuvenation” with Martin Braun, MD
  • “Maintenance of Certification Workshop (Self-Assessment Credit)” with Erik Stratman, MD
  • “Derm In-Review Board Review” with session chair and conference medical director Adam Friedman, MD (in partnership with George Washington University)

Additional Faculty

  • Joel L. Cohen, MD, vice conference chair
  • Susan H. Weinkle, MD, vice conference chair
  • Martin Braun, MD
  • Justin Finch, MD
  • Robert Gotkin, MD
  • Jeremy Green, MD
  • William Hanke, MD
  • John Harris, MD
  • Sima Jain, MD
  • Terrence Keaney, MD
  • Leon Kircik, MD
  • Yasmine Kirkorian, MD
  • Sailesh Konda, MD
  • Angelo Landriscina, MD
  • Kavita Mariwalla, MD
  • Amy McMichael, MD
  • Alan Menter, MD
  • David Miller, MD
  • Vishal Patel, MD
  • Desiree Ratner, MD
  • Victor Ross, MD
  • Deborah S. Sarnoff, MD
  • Linda Stein Gold, MD
  • Erik Stratman, MD
  • Jackie Yee, MD
  • Jonathan Zippin, MD

Attendees may visit the exhibit hall that showcases the latest innovations in dermatology by more than 70 companies. In addition, more than 80 research and case study posters are available for viewing. The Advanced Resident Training and Education (ARTE) scholarship program provides the ODAC learning experience to more than 100 future dermatologists.

ODAC is a product of SanovaWorks, publisher of the Journal of Drugs in Dermatology (JDD) and producer of the Skin of Color Update conference.

Registration is available at orlandoderm.org.

Skin of Color Update Press Coverage

SKIN OF COLOR UPDATE 2019 COVERAGE

By | Press, Skin of Color, Skin of Color Update

NEW YORK (Oct. 15, 2019) Skin of Color Update 2019 continues to receive coverage from various media outlets after producing a sold out event.  A SanovaLive event, Skin of Color Update, Sept. 7 & 8, 2019 at the Crowne Plaza Times Square hosted an expert faculty with 2 days education, networking and discovery.  This 2-day event attracted over 300 dermatology providers from all over the US. Missed the event? Purchase it on-demand here.

See what the media has to say about the event and register for Skin of Color Update 2020 before it sells out.

The Dermatologist covered Wendy Roberts, MD session on Hair and Scalp Disorders: A Review of Alternative Therapies


In an interview with The Dermatologist, Skin of Color Update presenter Cheryl M. Burgess, MD, discusses  her lecture on common cosmetic concerns among patients with skin of color and the importance of recognizing adverse reactions.


Sun protection in Skin of Color patients still matters. Find out what Henry Lim, MD had to say in an interview with The Dermatologist regarding his lecture at Skin of Color Update 2019.  Read more.


Skin of Color Update speaker Theodore Rosen, MD presented on hidradenitis suppurativa in the black community and the improvement of disease control.  Read an overview of his session here.


Andrew Alexis, MD presented clinical findings on new drugs that particularly benefit skin of color patients with acne. Read the overview on Dermatology News.


Skin of color poses some unique challenges when it comes to diagnosing atopic dermatitis (AD). In a recent interview, co-founder and co-chair Andrew Alexis, MD discusses his challenges and pearls for treating AD in skin of color.  Read more.


Dermatology News recently covered Wendy Roberts, MD Skin of Color Update 2019 presentation on combination treatments for pseudofolliculitis barbae.  Read the interview and more here.


Whitening of skin remained charged topic at the recent Skin of Color Update, co-founder and co-chair Eliot F. Battle, Jr. MD lead the discussion with an interesting expert opinion on the topic.  Read more.


Register for Skin of Color Update at the Sheridan Times Square, September 12 and 13, 2020.

Purchase Skin of Color Update On-Demand:

Skin of Color Update Dermatology On-Demand

ODAC 2020 ARTE Dermatology Resident Scholarships

DERMATOLOGY RESIDENT SCHOLARSHIPS FOR ODAC 2020

By | ODAC, Residents

ORLANDO (updated Oct.16, 2019) ODAC Dermatology, Aesthetic and Surgical (ODAC) conference announced the first round of dermatology resident scholarships for the January 17 – 20, 2020 meeting at the JW Marriott, Orlando, Florida.

ODAC has awarded over 3,000 dermatology resident scholarships over 16 years, and is hailed the #1 and largest scholarship program for dermatology meetings.

Each year, nearly 900 dermatologists and allied health professionals attend ODAC making it one of the largest medical, aesthetic and surgical dermatology conferences in the United States.  Of the 900 attendees, ODAC hosts over 150 US dermatology residents as part of the Advanced Resident Training Education (ARTE) Scholarship program.

Dermatology residents attending ODAC have the opportunity to be paired one-on-one with a mentor, publish with media partners, and present an abstract in the Annual ARTE Scholar Poster Session.  ODAC offers content specifically designed for the dermatologist-in-training including:

  • Dermatology In-Review Board Review Session hosted in conjunction with George Washington University
  • Resident Program Track with specific talks and workshops of most relevance for the resident attendee
  • 17th Annual Hands-On Aesthetic Training Workshop
  • 10th Annual Resident ARTE Scholar Poster Competition
  • Pair one-on-one with an expert mentor in the dermatology field
  • Publish in Next Steps in Derm

From July to October 18th, ODAC accepts over 500 scholarship applications from dermatology residents training at over 160 US Dermatology Residency programs for MD and DO.  Resident applicants submit their C.V., a letter of good standing for their residency and compete with other program residents for the coveted scholarship positions.

On behalf of SanovaWorks,  we would like to congrats the first and second round of ARTE Scholar Awardees:

Blair Saunders Allais MD
Kathryn Lee Anderson MD
Brandon Michael Basehore DO
Cassandra Beard DO
Lisa Bedford MD
Hamza Dastgir Bhatti DO
Nathan Bibliowicz DO
Nikoleta Brankov MD
Margaret E Brown MD
Soham Chaudhari DO
Judy Cheng MD
Hassie Cooper DO
Megan Cronin MD
George Olen Denny MD, MS
Shannon Quirk Detty MD
Ashley Marie Dietrich MD
Andrew Spiros Dorizas MD
Andrew Colin Duncanson DO
Misty Eleryan MD, MS
Amarachi Chioma Eseonu MD
Jessica Feig MD PhD
Aaron Yeu Wah Fong MD
Fabrizio (Marina) Galimberti MD PhD
Zachary Gillooly MD
Sibel Gokce MD
Alexandra Grammenos DO
Anna Gregoire MD
Erica Ann Grilletta M.D.
Christopher Haley M.D.
Ingrid Herskovitz MD
Angela Hou MD
Gabriel Isaza-Gonzalez MD
Reshmi Kapoor MD
Genevieve York Kaunitz MD
Trisha Khanna md
Raymond Kleinfelder DO
Steven Krueger MD
Olivia Yu-Ping Lai MD
Yi Chun Lai MD, MPH
Krista Larson MD
Danielle Raffaella Lazzara DO
Ming Hua Lee MD
Yumeng Li MD MS
Xiaoxiao Li MD, PhD
Sarah Lonowski MD, MBA
Jason Mammino DO
Eric Maranda MD
Samantha Alexa Marrone MD
Jacqueline McKesey MD, MS
John Richard Moesch DO
Tasneem Mohammad MD
Tejaswi V Mudigonda MD
Robert D Murgia DO
Nicole Negbenebor MD
Kevin Nethers MD
Sarah Nichols MD
Timothy Nyckowski D.O.
Amit Om MD
Jigar Patel MD
Manoj Karbhari Pawar MD
Quy Pham MD
Ji Qi MD
Saleh Rachidi MD, PhD
Asmi Sanghvi DO
William Schaffenburg MD
Gene Schwartz MD
Mehreen Joy Sheikh DO
Betty Song MD
Olivera Stojadinovic MD
Shalini Thareja MD
Rebecca Stoner Thornhill MD
Jeffrey Wargo MD
Brooke Wehausen DO
Allison Weinkle MD
Annie Wester MD
Kiyanna Williams MD
Aubrey Elizabeth Winn MD
Yi Yang MD
Mina Zarei MD
Myron Zhang MD
Patrick Zito DO, PharmD

There is still time to apply! ODAC is accepting applications until October 18, 2019.  Apply now.

 

About ODAC

ODAC is the premier clinical dermatology conference expertly curated to provide comprehensive, annual updates and fresh pearls in medical, aesthetic and surgical dermatology.  The ODAC dermatology conference focuses on new uses for old treatments, incorporating new treatments, products and treatment lines, critical updates in diagnosis guidelines, as well as advanced techniques for enhancing your surgical and nonsurgical patient outcomes.

 

 

 

 

 

 

 

ndrew Alexis receiving JDD award for Innovations in Dermatology from Skin of Color Update

ANDREW F. ALEXIS, MD, MPH, PRESENTED WITH INNOVATIONS AWARD

By | Press

NEW YORK (Sept. 9, 2019) – The Journal of Drugs in Dermatology (JDD) presented dermatologist Andrew F. Alexis, MD, MPH, with the Innovations in Skin of Color Dermatology Award at Skin of Color Update, formerly Skin of Color Seminar Series, held September 7 and 8 in New York. The award recognizes individuals who have fostered innovation and improvement in dermatology through increased emphasis on skin of color education and research. If you missed the event, you can purchase lectures on-demand here.

“Andrew F. Alexis, MD, MPH is committed and passionate — not only about being the best dermatologist he can be – but also about bringing skin of color education to dermatology,” said Shelley Tanner, CEO and president of SanovaWorks, which produces the JDD and Skin of Color Update. “Through his efforts, the changing landscape of patients can now thrive through treatment and management plans that address their specific needs.”

“Dr. Alexis is the top innovator in the dermatologic and cosmetic treatment of patients with skin of color,” said dermatologist Eliot F. Battle, MD, co-chair of Skin of Color Update along with Dr. Alexis. “His decades of pioneering research in dermatology have led to the development of new procedures and products that address a wide range of dermatologic conditions. He compassionately treats his patients, shares his expertise by presenting throughout the world and gives back through mentoring the next generation of dermatologists and researchers. I am honored to serve alongside this distinguished innovator.”

Dr. Alexis is chair of the department of dermatology and director of the Skin of Color Center at Mount Sinai St. Luke’s and Mount Sinai West, New York. As such, he is actively involved in advancing patient care, research and education pertaining to dermatologic disorders that are prevalent in ethnic skin. He is also professor of dermatology at the Icahn School of Medicine at Mount Sinai.

Dr. Alexis received his medical degree from Columbia University College of Physicians & Surgeons and his Master of Public Health at Columbia University’s Mailman School of Public Health. He completed his dermatology residency at Weill Cornell Medical Center, followed by a fellowship in dermatopharmacology at New York University School of Medicine.

Dr. Alexis has published more than 70 articles in peer-reviewed journals and has co-edited two text books on dermatology for skin of color as well as authored 10 book chapters. He is a past president of the New York Dermatological Society and is currently chair of the Scientific Committee of the Skin of Color Society.

The recipient of the Innovations in Skin of Color Dermatology Award, given by the Journal of Drugs in Dermatology, is nominated and chosen through the recommendation of a panel of senior national thought-leaders in dermatology, a committee of dermatology practitioners and several industry leaders.

The Journal of Drugs in Dermatology (JDD), a full-color, peer-reviewed publication indexed with MEDLINE®/PubMed®, was founded by dermatologist Perry Robins, MD. Now in its 18th year, it offers one of the fastest routes to disseminate dermatologic information, and is considered the fastest growing publication in dermatology, presenting original articles, award-winning case reports and timely features pertaining to new methods, techniques and drug therapy that provide readers with peer-reviewed content of the utmost quality. The JDD is overseen by an International Editorial Board of more than 160 renowned experts and reaches more than 30,000 dermatology healthcare practitioners worldwide.

Skin of Color Update 2020 will be held September 12th – 13th at the Sheraton Times Square.

Media Contact:
Allison Sit
[email protected]

Purchase Skin of Color Update On-Demand: 

Skin of Color Update Dermatology On-Demand

Adam Friedman at ODAC

GW RESEARCHERS IDENTIFY BARRIER TO FUNGAL INFECTION DIAGNOSIS

By | Press

In a recent survey, researchers identified the barriers to accurately diagnosing cutaneous fungal infections

August 8, 2019

WASHINGTON (Aug. 8, 2019) —There are several barriers that prevent the consistent use of fungal diagnostic preparations to correctly identify cutaneous fungal infections, according to a survey from a team at the George Washington University (GW). The study is published in the Journal of Drugs in Dermatology.

Cutaneous fungal infections account for between 3.5 and 6.5 million dermatologist office visits per year. Despite their frequency, the diverse presentations of fungal infections often lead to misdiagnosis, resulting in additional costs, time, and delays in proper care. Direct microscopy using potassium hydroxide (KOH) or other stains provides an inexpensive method to diagnose fungal infections. However, this requires clinics to have the Clinical Laboratory Improvement Amendment (CLIA) certification.

“Because of the extraordinary ability for these fungal infections to mimic other skin diseases, identification based on clinical inspection alone can often lead to misdiagnosis and mismanagement,” said Adam Friedman, MD, professor and interim chair of the Department of Dermatology at the GW School of Medicine and Health Sciences and senior author on the study. “Little is known regarding the frequency with which dermatologists use these simple, yet diagnosis changing bedside fungal preparations, nor do we know if and what barriers exist preventing accurate diagnosis of infections.”

Friedman’s team previously published research highlighting the difficulty even dermatologists have when distinguishing between skin fungal infections and other inflammatory skin diseases, highlighting the importance of using laboratory-based tools to aid in patient care.

This survey, led by Emily Murphy, a research fellow in the Department of Dermatology at the GW School of Medicine and Health Sciences, was distributed via email to participants of the ODAC Dermatology Aesthetic and Surgical Conference, and the data was compiled in a web-based platform. Of the respondents, around 21% indicated they rarely/never perform fungal preparations and about 20% reported they sometimes do, often because they think clinical diagnosis is adequate or because fungal preparations take too long. Additionally, about 21% of respondents reported not having CLIA certifications, mostly because the process requires too much work or because they do not know how to apply. Of the providers who have CLIA certification, more than 25% reported that it was difficult to obtain.

“Our results indicate the need for increased education about the many clinical faces of cutaneous fungal infections and proper use of bedside diagnostics,” Friedman said. “It also highlights the need for policy-based interventions in order to ease the process of CLIA certification, to ensure that dermatology clinics are equipped to accurately diagnose infections.”

The study, titled “Use of In-Office Preparations by Dermatologists for the Diagnosis of Cutaneous Fungal Infections,” published in the Journal of Drugs in Dermatology can be found at jddonline.com/articles/dermatology/S1545961619P0798X/1/.

Media: For more information or to set up an interview, please contact Ashley Rizzardo at [email protected] or 202-994-8679.

###

About the GW School of Medicine and Health Sciences
Founded in 1824, the GW School of Medicine and Health Sciences (SMHS) was the first medical school in the nation’s capital and is the 11th oldest in the country. Working together in our nation’s capital, with integrity and resolve, the GW SMHS is committed to improving the health and well-being of our local, national and global communities. smhs.gwu.edu

All new JDDonline.com

NEWLY REDESIGNED JDDONLINE PROVIDES FASTER, MORE USER-FRIENDLY

By | Press

NEWLY REDESIGNED JDDONLINE PROVIDES FASTER, MORE USER-FRIENDLY

ACCESS TO THE JOURNAL OF DRUGS IN DERMATOLOGY

New York (June 18, 2019)– The Journal of Drugs in Dermatology (JDD) has a newly revamped website, JDDonline.com, which offers a fully-responsive design for more user-friendly browsing. With updated navigation, seamless transition from desktop to mobile viewing and new search features, subscribers are able to access JDD content, renew their subscriptions and view multimedia faster and easier than ever before.

“Our goal is to get the latest dermatologic research into the hands of clinicians as quickly and easily as possible so that the latest advancements can be further researched and implemented,” said Shelley Tanner, CEO and president of SanovaWorks, parent company of the JDD.

The redesigned site makes it easier to navigate the journal’s award-winning content, including multimedia, such as the JDD Podcastand Translational Lecture Series. In addition, subscribers can view PDFs of articles and archived issues.

The journal has also launched a new manuscript submission and peer-review site. The updated, streamlined submission process facilitates compliance with publishing requirements and allows fast, easy upload of manuscript files, figures and materials. The manuscript submission site can be accessed from JDDonline.comby clicking on the Authors tab at the top of the page or by visiting the site directly at jdd.msubmit.net.

“The manuscript submission process is easy to follow, which ensures completeness, quality control and timely submission,” Tanner said. “From the submission process to the final product, the Journal of Drugs in Dermatologystrives to be the leader in dermatologic publishing.”

The Journal of Drugs in Dermatology (JDD), a full-color, peer-reviewed publication indexed with MEDLINE®/PubMed®, was founded by dermatologist Perry Robins, MD. Now in its 18th year, it offers one of the fastest routes to disseminate dermatologic information, and is considered the fastest growing publication in dermatology, presenting original articles, award-winning case reports and timely features pertaining to new methods, techniques and drug therapy that provide readers with peer-reviewed content of the utmost quality. The JDD is overseen by an International Editorial Board of more than 160 renowned experts and reaches more than 30,000 dermatology healthcare practitioners worldwide.

 

Media Contact:

Allison Sit

[email protected]

Burt's Bees and Dermatology Journal of Drugs in Dermatology study

JDD PUBLISHES STUDY ON CLINICAL IMPROVEMENTS WITH BURT’S BEES’ SENSITIVE SKIN REGIMEN AS ADJUNCT TO ROSACEA THERAPY

By | Press

Journal of Drugs in Dermatology Publishes Study Showcasing Clinical Improvements with Burt’s Bees’ Sensitive Skin Regimen as Adjunct to Rosacea Prescription Therapy

Data Demonstrating Regimen’s Outperformance of a Dermatologist-Recommended Control to be presented at American Academy of Dermatology Annual Meeting

DURHAM, N.C.–(BUSINESS WIRE)–Burt’s Bees, a leading provider of personal care products committed to natural health and beauty solutions, today announced that the Journal of Drugs in Dermatology has published clinical data supporting the efficacy and tolerability of Burt’s Bees skin care products as an adjunct to rosacea prescription therapy. Abstracts outlining the study data will be shared at the American Academy of Dermatology Annual Meeting on March 1-5, 2019, in Washington, D.C.

For access to the manuscript click here.

Click here to read the complete press release.

Dr. Alan Menter at ODAC Award from JDD

ALAN MENTER, MD, HONORED BY ODAC AND THE JOURNAL OF DRUGS IN DERMATOLOGY

By | Press

ALAN MENTER, MD, HONORED BY ODAC AND THE JOURNAL OF DRUGS IN DERMATOLOGY

ORLANDO, Fla. (Jan. 22, 2019) – The ODAC Dermatology, Aesthetics & Surgical Conference, in partnership with the Journal of Drugs in Dermatology (JDD), honored dermatologist Alan Menter, MD, with the Outstanding Researcher & Educator in Psoriatic Disease Award at the conference held January 18-21 in Orlando, Fla. The award recognizes Dr. Menter’s significant contribution and lifetime commitment to the advancement of psoriatic disease research as well as his work guiding the next generation of psoriasis experts and researchers.

“Dr. Menter has dedicated his career to improving psoriasis treatment options and standards of care while also pouring countless hours into up-and-coming psoriasis experts and researchers, ensuring his legacy will continue for generations to come,” said Shelley Tanner, CEO and president of SanovaWorks, which produces the JDD and ODAC.

Bobby Mansouri, MD, became a dermatologist after serving as a research fellow under Dr. Menter and, as such, gives testimony to Dr. Menter’s impact on dermatologists and their patients.

“Dr. Menter has led the way as a champion for psoriatic disease,” said Dr. Mansouri. “It is because of people like Dr. Menter that the newest generation of dermatologists will thankfully never know the full struggle of managing psoriatic patients without targeted therapies. His dedication to psoriasis and research is one of the major reasons thousands upon thousands of patients finally have their psoriasis controlled.”

Dr. Menter is the chair of the Department of Dermatology and director of the Dermatology Residency program at Baylor University Medical Center in Dallas. In 2018, he was awarded Top Dermatologist of the Year by the International Association of Top Professionals, and in 2013, he received the Lifetime Achievement Award from the National Psoriasis Foundation. He founded the International Psoriasis Council in 2003. Dr. Menter is currently co-chair of the American Academy of Dermatology Psoriasis Guideline Work Group. He has served as an ODAC faculty member for two consecutive years.

The recipient of the Outstanding Researcher & Educator in Psoriatic Disease Award, given by the Journal of Drugs in Dermatology, is nominated and chosen through the recommendation of a panel of senior national thought-leaders in dermatology, a committee of dermatology practitioners and several industry leaders. The Journal of Drugs in Dermatology (JDD), a full-color, peer-reviewed publication indexed with MEDLINE®/PubMed®, was founded by dermatologist Perry Robins, MD. Now in its 18th year, it offers one of the fastest routes to disseminate dermatologic information, and is considered the fastest growing publication in dermatology, presenting original articles, award-winning case reports, and timely features pertaining to new methods, techniques, and drug therapy in dermatology, which provide readers with peer-reviewed content of the utmost quality. The JDD is overseen by an International Editorial Board of more than 160 renowned experts and reaches more than 30,000 dermatology healthcare practitioners worldwide.

###

Eliot Battle Skin of Color Award Dermatology Conference

ELIOT F. BATTLE, MD RECEIVES INNOVATIONS IN SKIN OF COLOR DERMATOLOGY AWARD

By | Press

JUNE 1, 2018

Eliot Battle, M.D., was awarded the Innovations in Skin of Color Dermatology Award by the Journal of Drugs in Dermatology at the Skin of Color Seminar Series (SOCSS) held in May in New York.

Dr. Battle, who is co-founder and co-chair of SOCSS, was recognized for his contributions in fostering innovation and improvement in dermatology through increased emphasis on skin of color education and research.

“Dr. Battle’s tireless support and advocacy has been instrumental in starting the industry wide shift towards dermatology education that is inclusive of all skin types,” said Shelley Tanner, CEO and president of SanovaWorks, which produces JDD and SOCSS. “Dr. Battle received the award for his commitment to safe, accessible, and cutting-edge dermatology care for patients of all ethnicities and for being a champion for this cause.”

Dr. Battle is CEO and founder of Cultura Cosmetic Dermatology and Laser Center in Washington, D.C. He is also the recipient of many national academic honors and awards, including having been inducted into the Alpha Omega Alpha medical honor society.

His research with Harvard Medical School helped usher in a new generation of non-invasive “color blind” cosmetic lasers. Dr. Battle is a member of the American Academy of Dermatology, American Society of Laser Medicine and Surgery and several international societies. In addition, Dr. Battle is past chairman of the dermatology section of the National Medical Association and past president of the Howard University Medical Alumni Association. He is on the medical staff at Howard University Hospital in the department of dermatology.

The recipient of the Innovations in Skin of Color Dermatology Award, given by the Journal of Drugs in Dermatology, is nominated and chosen through the recommendation of a panel of senior national thought-leaders in dermatology, a committee of dermatology practitioners and several industry leaders.

Acne Genetic Twins Survey JDD

ACNE SURVEY AT WORLDS LARGEST TWINS CONVENTION AFFIRMS GENETIC LINK

By | Press

Study also reveals social and environmental factors that influence acne severity

NEW YORK, April 27, 2018 /PRNewswire/ — A survey of identical and fraternal twin pairs at the Twins Days Festival in Twinsburg, Ohio, and published in the April issue of the Journal of Drugs in Dermatology, shows the skin condition may be primarily caused by genetics. Study findings show the proportion of pairs where twins have acne was significantly higher in identical (64 percent) versus fraternal (49 percent) twins.

“Since identical twins have the same genetic makeup, they make the perfect study group to see if acne is caused more by genetics or environmental factors,” said dermatologist Elma Baron, MD, professor of dermatology at Case Western Reserve University, Cleveland, and chief of dermatology at Louis Stokes Cleveland VA Medical Center.

Participating in the survey were 202 (101 pairs) identical and 53 (26 sets) fraternal twins, including one set of fraternal triplets. Both groups were young, predominantly female and the majority of the participants were Fitzpatrick Skin Types II or III. The survey was conducted at the 2016 festival.

Researchers also attempted to determine social and environmental factors that influence acne severity. A twin-to-twin analysis of 56 identical twin pairs who had acne yet differed in self-reported severity revealed differences that may serve as triggers, including a high-glycemic diet, higher BMI, and lower frequency of exercise compared to twins without acne.

“There is some suggestion that factors other than genetics may contribute to acne severity,” said Dr. Baron. “As was demonstrated in our study and others, people genetically predisposed to acne can reduce the intake of sugar and refined carbohydrates to help keep acne on the mild side. Using cosmetics that are non-comodegenic can also help reduce acne severity.”

Survey participants were also asked additional health questions to discover possible associations with other health conditions. Identical twins with acne were found to have a higher incidence of polycystic ovarian syndrome (PCOS), anxiety and asthma.

“Other studies have linked acne with PCOS and anxiety, but further research is needed to determine if there is a true association between acne and asthma,” said Dr. Baron.

The study may be accessed at: http://jddonline.com/articles/dermatology/S1545961618P0380X/1.

The Journal of Drugs in Dermatology (JDD), a full-color, peer-reviewed publication indexed with MEDLINE®/PubMed®, was founded by dermatologist Perry Robins, MD. Now in its 17th year, it offers one of the fastest routes to disseminate dermatologic information, and is considered the fastest growing publication in dermatology, presenting original articles, award-winning case reports, and timely features pertaining to new methods, techniques, and drug therapy in dermatology, which provides readers with peer-reviewed content of the utmost quality. The JDD is overseen by an International Editorial Board of more than 150 renowned experts and reaches more than 30,000 dermatology healthcare practitioners worldwide. The JDD is a product of SanovaWorks.

Media Contact:
Allison Sit
[email protected]

SOURCE SanovaWorks